Shen Fangcheng, Li Jing, Liu Feng, Sun Ni, Qiu XiangNan, Ding Wei, Sun XiangDong
Radiotherapy Department, Nanjing JinLing Hospital, Xuanwu District, Nanjing, Jiangsu, China.
Front Oncol. 2023 Feb 17;13:1095362. doi: 10.3389/fonc.2023.1095362. eCollection 2023.
Anlotinib, a novel multi-kinase inhibitor, was found to improve progression-free survival (PFS) in brain metastases.
This paper retrospectively analyzed 26 newly diagnosed or recurrent high-grade gliomas from 2017 to 2022, and the patients received oral anlotinib during concurrent postoperative chemoradiotherapy or after recurrence. Efficacy was evaluated according to the Response Assessment in Neuro-Oncology (RANO) criteria, and the main study endpoints were PFS at 6 months and overall survival (OS) at 1 year.
After the follow-up, until May 2022, 13 patients survived and 13 patients died, with a median follow-up time of 25.6 months. The disease control rate (DCR) was 96.2% (25/26), and the overall response rate (ORR) rate was 73.1% (19/26). The median PFS after oral anlotinib was 8.9 months (0.8-15.1), and the PFS at 6 months was 72.5%. The median OS after oral anlotinib was 12 months (1.6-24.4), and the OS at 12 months was 42.6%. Anlotinib-related toxicities were observed in 11 patients, mostly grades 1-2. In the multivariate analysis, patients with Karnofsky Performance Scale (KPS) above 80 had a highermedian PFS of 9.9months (p = 0.02), and their sex, age, IDH mutation, MGMTmethylation, and whether anlotinib was combined with chemoradiotherapy or maintenance treatment had no effect on PFS.
We found that anlotinib combined with chemoradiotherapy in treating high-grade central nervous system (CNS) tumors can prolong PFS and OS and that it was safe.
安罗替尼是一种新型多激酶抑制剂，已被发现可改善脑转移患者的无进展生存期（PFS）。
本文回顾性分析了2017年至2022年期间26例新诊断或复发的高级别胶质瘤患者，这些患者在术后同步放化疗期间或复发后接受了安罗替尼口服治疗。根据神经肿瘤学疗效评估（RANO）标准评估疗效，主要研究终点为6个月时的PFS和1年时的总生存期（OS）。
随访至2022年5月，13例患者存活，13例患者死亡，中位随访时间为25.6个月。疾病控制率（DCR）为96.2%（25/26），总缓解率（ORR）为73.1%（19/26）。口服安罗替尼后的中位PFS为8.9个月（0.8 - 15.1），6个月时的PFS为72.5%。口服安罗替尼后的中位OS为12个月（1.6 - 24.4），12个月时的OS为42.6%。11例患者观察到与安罗替尼相关的毒性，大多为1 - 2级。在多因素分析中，卡诺夫斯基功能状态评分（KPS）高于80的患者中位PFS较高，为9.9个月（p = 0.02），其性别、年龄、异柠檬酸脱氢酶（IDH）突变、O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）甲基化以及安罗替尼是否与放化疗联合或维持治疗对PFS均无影响。
我们发现安罗替尼联合放化疗治疗高级别中枢神经系统（CNS）肿瘤可延长PFS和OS，且安全性良好。
